Correlation between genetic typing and drug resistance of uropathogenic Escherichia coli

doi:10.3877/cma.j.issn.1674-1358.2018.02.011

Abstract

Abstract:

Objectives

To investigate the relationship between the multi-locus sequence typing (MLST) and the antimicrobial resistance of uropathogenic Escherichia coli (UPEC).

Methods

UPEC strains were isolated from patients in Putuo Hospital, Shanghai University of Traditional Chinese Medicine from March 2015 to December 2016. The strains were classified by MLST. The susceptibility to 17 kinds of common antimicrobial drugs and ESBLs identification of the UPEC were determined by Vitek-2 Compact.

Results

Among the 93 UPEC strains, the resistance rates to imipenem were 0%; which were 1.1%-3.2% to ertapenem, amikacin, piperacillin-tazobactam, still with high susceptibility. The resistance rates to ceftazidime, cefepime, ammonia QuNa, gentamicin, tobramycin were all < 50%, which displayed moderate susceptibility. The resistance rates to ceftriaxone, ciprofloxacin, levofloxacin and compound SMZ were all > 50%, which showed high resistance. Among the 93 UPEC strains, 59 (63.4%) strains produced ESBLs, 34 (36.6%) strains didn’t produce ESBLs. There were 33 known and 1 unknown sequence types (STs) detected from the isolated strains. The most frequent sequence types were ST131 (23/93, 24.7%), ST648 (9/93, 9.7%), ST405 (7/93, 7.5%) and ST1193 (7/93, 7.5%).

Conclusions

UPEC showed multi-drug resistance, and the MLST classification indicates that the UPEC strain was diverse, and ESBLs had a certain correlation with UPEC antibacterial drug resistance, and ST type had no correlation with drug resistance spectrum.

Key words: Uropathogenic Escherichia coli, Multi-locus sequence typing, Multidrug resistance, Extended spectrum bata lactarnase

Jinling Hong, Weizheng Li, Xuan Zhou, Dongying Xue, Junhua Dai, Jie Zhang. Correlation between genetic typing and drug resistance of uropathogenic Escherichia coli[J]. Chinese Journal of Experimental and Clinical Infectious Diseases(Electronic Edition), 2018, 12(02): 155-159.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhsyhlcgrbzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-1358.2018.02.011

https://zhsyhlcgrbzz.cma-cmc.com.cn/EN/Y2018/V12/I02/155

Figures/Tables 2

References 26

[1]	Jones RN, Kugler KC, Pfaller MA, et al. Characteristics of pathogens causing urinary tract infections in hospitals in North America: results from the SENTRY Antimicrobial Surveillance Program,1997[J]. Diagn Microbiol Infect Dis,1999,35(1):55-63.
[2]	童朝辉, 王臻, 王辰, 等. 医院获得性肺炎克雷伯菌和大肠埃希菌下呼吸道感染及耐药分析[J]. 中华医院感染杂志,2003,13(7):674-676.
[3]	上海市细菌耐药性监测协作组. 上海地区细菌耐药性监测[J]. 中国抗感染化疗杂志,2002,2(1):1-9.
[4]	Pitout JD, Laupland KB. Extended-spectrum beta-lactamase-producing Enterobacteriaceae: an emerging public-health concern[J]. Lancet Infect Dis,2008,8(3):159-166.
[5]	Dayan N, Dabbah H, Weissman I, et al. Urinary tract infections caused by community-acquired extended-spectrum β-lactamase-producing and nonproducing bacteria: a comparative study[J]. Pediatr.2013,163(5):1471-1421.
[6]	Xu Y, Bai X, Jin Y, et al. High prevalence of virulence genes in specific genotypes of atypical enteropathogenic Escherichia coli[J]. Front Cell Infect Microbiol,2017,4(7):109-120.
[7]	Tartof SY, Solberg OD, Manges AR, et al. Analysis of a uropathogenic Escherichia coli clonal group by multilocus sequence typing[J]. Clin Microbiol,2005,43(12):5860-5864.
[8]	Boucher HW, Talbot GH, Bradley JS, et al. Bad bugs, no drugs: no ESKAPA! An update from the Infectious Diseases Society of America[J]. Clin Infect Dis,2009,48(1):1-12.
[9]	Infectious Diseases Society of A, Spellberg B, Blaser M, et al. Combating antimicrobial resistance: policy recommendations to save lives[J]. Clin Infect Dis,2011,52(5):397-428.
[10]	李维正, 孙琳, 陈蓓, 等. 上海市一区级医院老年患者尿路致病性大肠埃希菌分子分型和耐药性分析[J]. 中华传染病杂志,2016,34(6):337-343.
[11]	胡付品, 朱德妹, 汪复, 等. 2014年CHINET中国细菌耐药性监测[J]. 中国感染与化疗杂志,2015,15(5):401-410.
[12]	Xia S, Fan X, Huang Z, et al. Dominance of CTX-M-type extended-spectrum β-lactamase(ESBL)-producing Escherichia coli isolated from patients with community-onset and hospital-onset infection in China[J]. PLoS One,2014,9(7):e100707.
[13]	Al-Agamy MH, Shibl AM, Hafez MM, et al. Molecular characteristics of extended-spectrum β-lactamase-producing Escherichia coli in Riyadh: emergence of CTX-M-15-producing E.coli ST131[J]. Ann Clin Microbiol Antimicrob,2014,13(1):4-10.
[14]	蒋伟, 王思淼, 金鑫, 等. 住院患者产CTX-M型ESBLs和KPC的大肠埃希菌感染分布与耐药基因分析[J]. 中国感染控制杂志,2016,15(10):760-763.
[15]	刘新明, 候红艳, 田磊, 等. 重症监护病房病原菌分布及耐药性分析[J]. 内科急危重症杂志,2015,21(1):34-37.
[16]	何卫平, 崔恩博, 王钱, 等. 235株血流感染大肠埃希菌耐药性分析 [J].中国感染控制杂志,2015,14(3):170-173.
[17]	陈如昌, 王利健. 2006-2009年重症监护病房医院感染大肠埃希菌与肺炎克雷伯菌的耐药性分析[J]. 中华医院感染学杂志,2011,(5):1013-1015.
[18]	吕卫东. 260株大肠埃希菌的耐药性分析[J]. 中华医院感染学志.2011,21(3):568-569.
[19]	王海, 汪宏良, 程攀. 产超广谱β-内酰胺酶肺炎克雷伯菌和大肠埃希菌的耐药性分析[J]. 实验与检验医学,2015,33(5):653-655.
[20]	唐春进, 杨淑雅, 赵瑞珂, 等. 医院获得性尿路感染大肠埃希菌ESBLs基因型与耐药分析[J]. 检验医学与临床,2016,13(6):734-740.
[21]	Popoff MY. Supplemengt 1997(No. 41) to the Kauffmann-White scheme [J]. Res Microbiol,1998,149(8):601-604.
[22]	Maiden MCJ. Multilocus sequence typing:a portable approach to the identification of clones within populations of pathogenic microorganisms[J]. Proc Natl Acad Sci USA,1998,95(6):3140-3145.
[23]	Peirano G, Richardson D, Nigrin J, et al. High prevalence of ST131 isolates producing CTX-M-15 and CTX-M-14 among extended-spectrum-beta-lactamase- producing Escherichia coli isolates from Canada[J]. Antimicrob Agents Chemother,2010,54(3):1327-1330.
[24]	秦晓华. 尿路致病性大肠埃希菌持留相关机制的研究[D]. 上海: 复旦大学,2012.
[25]	Hussain A, Ranjan A, Nandanwar N, et al. Genotypic and phnotypic profiles of Escherichia coli isolates belonging to clinical sequence type 131 (ST131), clinical non-ST131, and fecal non-131 lineages from India[J]. Antimicrob Agents and Chemother,2014,58(12):7240-7249.
[26]	Nicolas-Chanoine MH, Bertrand X, Madec JY. Escherichia coli ST131, an intriguing clonal group[J]. Clin Microbiol Rev,2014,27(3):543-574.

抗菌药物	大肠埃希菌（n = 93）	产ESBLs（n = 59）	非产ESBLs（n = 34）	χ²值	^aP值
阿米卡星	3.2	5.1	0.0	1.786	0.297
氨苄青霉素/舒巴坦	48.4	64.4	29.4	22.524	0.000
氨曲南	43.0	57.6	17.6	14.066	0.000
头孢唑林	71.0	88.1	41.2	23.089	0.000
头孢吡肟	32.3	42.4	14.7	11.458	0.003
头孢他啶	32.3	42.4	14.7	7.590	0.017
头孢曲松	54.8	83.1	14.7	34.854	0.000
环丙沙星	64.5	72.9	50.0	7.091	0.054
厄他培南	1.1	1.7	0.0	2.315	0.314
庆大霉素	46.5	52.5	35.3	2.581	0.108
亚胺培南	0.0	0.0	0.0	1.754	0.366
左氧氟沙星	52.7	66.1	29.4	12.961	0.001
呋喃妥因	15.1	22.0	3.0	7.884	0.019
哌拉西林/他唑巴坦	2.2	1.2	3.0	0.682	0.711
妥布霉素	20.4	28.2	8.8	7.995	0.018
复方SMZ	60.2	66.1	50.0	2.334	0.127
氨苄西林	88.2	94.9	76.5	7.389	0.024

抗菌药物	大肠埃希菌（n = 93）	产ESBLs（n = 59）	非产ESBLs（n = 34）	χ²值	^aP值
阿米卡星	3.2	5.1	0.0	1.786	0.297
氨苄青霉素/舒巴坦	48.4	64.4	29.4	22.524	0.000
氨曲南	43.0	57.6	17.6	14.066	0.000
头孢唑林	71.0	88.1	41.2	23.089	0.000
头孢吡肟	32.3	42.4	14.7	11.458	0.003
头孢他啶	32.3	42.4	14.7	7.590	0.017
头孢曲松	54.8	83.1	14.7	34.854	0.000
环丙沙星	64.5	72.9	50.0	7.091	0.054
厄他培南	1.1	1.7	0.0	2.315	0.314
庆大霉素	46.5	52.5	35.3	2.581	0.108
亚胺培南	0.0	0.0	0.0	1.754	0.366
左氧氟沙星	52.7	66.1	29.4	12.961	0.001
呋喃妥因	15.1	22.0	3.0	7.884	0.019
哌拉西林/他唑巴坦	2.2	1.2	3.0	0.682	0.711
妥布霉素	20.4	28.2	8.8	7.995	0.018
复方SMZ	60.2	66.1	50.0	2.334	0.127
氨苄西林	88.2	94.9	76.5	7.389	0.024

抗菌药物	ST131（23株）	其他ST型（70株）	χ²值	^aP值
阿米卡星	4.3	2.9	0.123	1.000
氨苄青霉素/舒巴坦	47.8	20.0	8.316	0.016
氨曲南	52.2	40.0	1.047	0.306
头孢唑林	60.9	74.3	1.512	0.219
头孢吡肟	30.4	32.9	0.047	0.977
头孢他啶	13.0	38.6	5.205	0.054
头孢曲松	47.8	57.1	0.607	0.436
环丙沙星	78.3	60.0	2.784	0.426
厄他培南	0.0	1.4	0.672	0.715
亚胺培南	0.0	0.0	0.000	1.000
左氧氟沙星	52.2	52.9	0.347	0.841
庆大霉素	60.9	48.5	2.632	0.105
呋喃妥因	8.7	17.1	1.309	0.520
哌拉西林/他唑巴坦	0.0	2.9	2.876	0.237
妥布霉素	17.4	21.4	0.180	0.914
复方SMZ	56.5	61.4	0.174	0.677
氨苄西林	91.3	87.9	0.483	0.786

抗菌药物	ST131（23株）	其他ST型（70株）	χ²值	^aP值
阿米卡星	4.3	2.9	0.123	1.000
氨苄青霉素/舒巴坦	47.8	20.0	8.316	0.016
氨曲南	52.2	40.0	1.047	0.306
头孢唑林	60.9	74.3	1.512	0.219
头孢吡肟	30.4	32.9	0.047	0.977
头孢他啶	13.0	38.6	5.205	0.054
头孢曲松	47.8	57.1	0.607	0.436
环丙沙星	78.3	60.0	2.784	0.426
厄他培南	0.0	1.4	0.672	0.715
亚胺培南	0.0	0.0	0.000	1.000
左氧氟沙星	52.2	52.9	0.347	0.841
庆大霉素	60.9	48.5	2.632	0.105
呋喃妥因	8.7	17.1	1.309	0.520
哌拉西林/他唑巴坦	0.0	2.9	2.876	0.237
妥布霉素	17.4	21.4	0.180	0.914
复方SMZ	56.5	61.4	0.174	0.677
氨苄西林	91.3	87.9	0.483	0.786

Please choose a citation manager

Content to export